We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Liver Disease in Kidney Transplant Patients Receiving Azathioprine

Patricia Ireland, MD; Abdur Rashid, MD, FRCP (C); Franz von Lichtenberg, MD; Tito Cavallo, MD; John P. Merrill, MD
Arch Intern Med. 1973;132(1):29-37. doi:10.1001/archinte.1973.03650070021004.
Text Size: A A A
Published online


The liver disease in 24 kidney transplant patients receiving azathioprine was reviewed to determine the cause and appropriate management. Azathioprine hepatotoxicity could not be implicated in any of the 24 patients, and there was no correlation between the course of the liver disease and azathioprine administration and withdrawal. Seven patients had "nonspecific reactive hepatitis" associated with sepsis and other complications; 12 patients had viral hepatitis, based on the clinical course, histopathologic and laboratory findings, and tests for Australia antigen; and in five patients the cause of the liver disease could not be determined. The high morbidity of viral hepatitis in these patients (fulminant hepatitis in one and post-necrotic cirrhosis in two) suggested an adverse effect of immunosuppression. Liver disease is not an indication to discontinue azathioprine therapy, but rather to reduce total immunosuppression whenever possible.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.